骨形态发生蛋白诱导骨髓间充质干细胞成骨分化的研究进展

目前从骨髓中成功分离、鉴定BMSCs的方法较为成熟。新发现一些物质能诱导BMSCs向成骨细胞分化因子,其中对BMP研究较多。其机制可能是通过结合Ⅰ、Ⅱ型BMP受体后激活Smad信号通路诱导成骨。其诱导方法主要包括直接应用天然BMP或者将BMP及其协同基因转入BMSCs,通过靶细胞的持续表达BMP促进新骨形成。本文将近10年BMP诱导BMSCs向成骨分化的研究现状及发展趋势做一综述。     

骨形态发生蛋白9通过JNKs激酶途径调控间充质干细胞成骨分化

前期研究发现骨形态发生蛋白9(bone morphogenetic protein 9,BMP9)除了通过经典Smad途径外,也可通过丝裂原活化蛋白激酶(mitogen activated protein kinases,MAPKs)中的p38激酶途径调控间充质干细胞成骨分化．本研究继续探讨MAPKs的重要成员c-Jun氨基末端激酶(c-Jun N-terminal kinases,JNKs)对于BMP9诱导间充质干细胞成骨分化的调控作用．利用BMP9重组腺病毒感染间充质干细胞,通过体外细胞实验和体内动物实验,初步分析BMP9是否可通过JNKs激酶途径调控间充质干细胞成骨分化．结果表明：BMP9可通过促进JNKs激酶磷酸化而导致其活化;JNKs抑制剂SP600125可抑制由BMP9诱导的间充质干细胞的碱性磷酸酶(alkaline phosphatase,ALP)活性、骨桥蛋白(osteocpontin,OPN)和骨钙素(osteocalcin,OCN)表达以及钙盐沉积;利用抑制剂SP600125抑制JNKs激酶活性后,BMP9诱导Runx2的表达和转录活性,以及Smad经典途径的激活也相应受到抑制;RNA干扰导致JNKs基因沉默同样也可抑制BMP9诱导的间充质干细胞成骨分化以及裸鼠皮下异位成骨．因此,BMP9可通过活化JNKs激酶途径,从而调控间充质干细胞成骨分化．     

骨形态发生蛋白家族及其受体在生殖调控中的作用

骨形态发生蛋白 (bonemorphogenelicprotein ,BMP)又称骨形成蛋白 ,属于转化生长因子超家族成员。本文从理化特性、受体种类、信号转导机制 ,以及在动物生殖调控中的作用和受体基因突变所导致的多胎机制等方面 ,详细阐述了有关BMP近年来的研究状况 ,旨在为研究绵羊或其它物种的多胎机制提供参考     

骨形态发生蛋白在神经系统中的表达和功能研究进展

近年来,骨形态发生蛋白（bone morphogenetic proteins,BMPs）在神经系统中的功能越来越受到人们的关注,现已发现,不同亚型的BMPs在神经系统中的不同区域呈持续性表达,一系列体外和体内动物实验证明BMPs不仅在神经系统发育过程中发挥重要作用,并且在成熟神经系统受到损伤时具有神经保护和神经再生功能,其确切机制有待通过实验进一步阐明。     

骨形态发生蛋白7 在前列腺癌中的表达

目的:探讨骨形态发生蛋白( BMP-7)在前列腺癌组织中的表达及其与临床分期之间的关系.方法:应用免疫印迹法检测30例前列腺癌患者及30例前列腺良性增生患者前列腺组织中BMP-7的表达情况.结果:前列腺癌组织中BMP-7的表达显著高于前列腺良性增生组织,且BMP-7的表达随前列腺癌的临床分期、Gleason分级增高而增加.结论:BMP-7在前列腺癌中的表达明显增高,其表达量与临床分期相关,前列腺癌组织中BMP-7的表达增高提示预后不佳.     

阻断ERK1/2激酶可增强骨形态发生蛋白9诱导的间充质干细胞成骨分化

骨形态发生蛋白9(bone morphogenetic protein 9,BMP9)具有很强的诱导间充质干细胞定向成骨分化的能力.但对于其所涉及的相关分子机理了解并不深入.利用BMP9重组腺病毒感染间充质干细胞,Western blot检测ERK1/2激酶的磷酸化,ERK1/2的特异性抑制剂PD98059阻断ERK1/2活性,或以RNA干扰抑制ERK1/2表达,通过体外细胞实验和体内动物实验,初步分析和揭示ERK1/2对于BMP9诱导的间充质干细胞成骨分化的调控作用及其可能机制.结果发现:BMP9可以促进ERK1/2激酶的磷酸化,ERK1/2抑制剂PD98059可增强由BMP9诱导的碱性磷酸酶(alkaline phosphatase,ALP)活性、骨桥蛋白(osteopontin,OPN)表达和钙盐沉积,并促进由BMP9诱导的Runx2基因的表达和转录活性,以及Smad经典途径的活化;而RNA干扰导致ERK1/2基因沉默同样也可进一步促进BMP9诱导的ALP活性和钙盐沉积,并促进BMP9诱导的间充质干细胞在裸鼠皮下异位成骨.因此,BMP9可以促进ERK1/2蛋白激酶的活化,而阻断ERK1/2蛋白激酶可进一步增强BMP9诱导的成骨分化,ERK1/2极可能对于BMP9诱导的间充质干细胞成骨分化起着负向调控作用.     

骨形态发生蛋白与细胞外基质磷酸化糖蛋白相关性研究进展

骨形态发生蛋白(BMP)是转化生长因子β超家族成员,细胞外基质磷酸化糖蛋白(MEPE)是一种细胞外基质的非胶原磷酸化糖蛋白,两者都是成骨信号通路中的重要蛋白。近年来发现MEPE表达水平受BMP的调节,并在磷酸盐代谢调节、成骨细胞增殖分化中发挥重要作用,同时与肿瘤细胞的骨转移有着密切的关联。在此,我们简要综述近年来BMP与MEPE的关系以及它们在肿瘤细胞骨转移方面的作用。     

重组骨形态发生蛋白-7在骨损伤疾病治疗中的研究进展

骨形态发生蛋白-7(BMP-7)是具有强诱骨活性的蛋白质因子,已通过基因工程技术在体外得到表达,较长时间以来不断被应用于骨损伤疾病的研究,得到了确切的治疗效果。通过载体将BMP-7基因转入真核细胞,与生物聚合载体复合后植入体内,能表达并分泌活性的BMP-7,诱导骨细胞的生成,促进骨组织的修复,成为一种新的有效的治疗手段。     

研究报告：骨形态发生蛋白9通过p38激酶途径调控间充质干细胞C3H10T1/2成骨分化

前期研究发现骨形态发生蛋白9(bone morphogenetic protein 9,BMP9)具有较强的诱导间充质干细胞成骨分化的能力.为进一步揭示其诱导和调控间充质干细胞成骨分化的机理,利用BMP9重组腺病毒感染间充质干细胞C3H10T1/2,通过体外细胞实验和体内动物实验,初步分析BMP9是否可通过p38激酶途径调控间充质干细胞成骨分化.结果发现,BMP9可以通过促进p38激酶磷酸化而导致其活化,p38抑制剂SB203580可抑制由BMP9诱导的C3H10T1/2细胞的碱性磷酸酶(alkalinephosphatase,ALP)活性、骨桥蛋白(osteopontin,OPN)表达和钙盐沉积,而且利用抑制剂SB203580抑制p38激酶活性后,BMP9诱导的Smad经典途径的激活也相应受到抑制,RNA干扰导致p38基因沉默同样也可抑制BMP9诱导的ALP活性、OPN表达、钙盐沉积以及裸鼠皮下异位成骨.因此,BMP9可通过活化p38激酶途径调控间充质干细胞C3H10T1/2成骨分化.     

骨形态发生蛋白的受体及其信号传递过程

近年来已克隆出几种Ⅰ型和Ⅱ型BMP受体.BMP受体属于TGFβ受体超家族的成员,具有丝氨酸/苏氨酸蛋白激酶活性.Ⅰ型与Ⅱ型BMP受体均可与BMP配基结合,但若执行传递信号功能,两受体需首先形成复合物.删除突变和基因剔除研究证明,ⅠA型BMP受体对动物的中胚层发育至关重要.而ⅠB型BMP受体在软骨细胞形成、成骨细胞分化以及程序化细胞死亡方面起主要作用.BMP受体信号传递分子Smad 1和Smad 5也已被克隆和鉴定,它们在BMP受体介导的功能中起重要作用.     

Notch信号参与BMP4诱导的间充质干细胞成骨分化及其机制的初步探讨

目的:探讨Notch信号对骨形态发生蛋白4(bone morphogenetic protein 4,BMP4)诱导间充质干细胞成骨分化的影响以及作用机制。方法:(1)DAPT或Ad-dominant-negative mutants of Notch1(Addn Notch1)和BMP4-CM处理小鼠胚胎成纤维细胞,检测早期成骨指标碱性磷酸酶(alkaline phosphatase,ALP);(2)茜素红S染色实验检测晚期成骨钙盐沉积情况;(3)半定量反转录聚合酶链反应(RT-PCR)检测成骨分化相关基因ALP,Runx2,Col1a1的表达;(4)免疫细胞化学检测p-Smad1/5/8的表达;(5)结晶紫染色和流式细胞术检测细胞的增殖及周期改变。结果:(1)DAPT抑制BMP4诱导的早期成骨分化,且呈浓度依赖性;(2)Delta-like 1(DLL1)促进BMP4诱导的成骨分化,DAPT和dn Notch1抑制BMP4诱导的成骨分化;(3)DLL1促进BMP4诱导的成骨相关基因ALP,Runx2,Col1a1的表达,DAPT抑制这些基因的表达;(4)DLL1促进BMP4诱导的细胞核内p-Smad1/5/8的表达,而DAPT抑制其表达;(5)DLL1促进BMP4诱导的细胞增殖,而DAPT抑制BMP4诱导的细胞增殖。结论:Notch信号通过BMP/Smads信号通路促进BMP4诱导的MSCs成骨分化,在此过程中也有促细胞增殖的作用。     

Bone Morphogenetic Protein 4 (BMP4) Enhances the Differentiation of Human Induced Pluripotent Stem Cells into Limbal Progenitor Cells

Corneal epithelium maintains visual acuity and is regenerated by the proliferation and differentiation of limbal progenitor cells. Transplantation of human limbal progenitor cells could restore the integrity and functionality of the corneal surface in patients with limbal stem cell deficiency. However, multiple protocols are employed to differentiate human induced pluripotent stem (iPS) cells into corneal epithelium or limbal progenitor cells. The aim of this study was to optimize a protocol that uses bone morphogenetic protein 4 (BMP4) and limbal cell-specific medium. Human dermal fibroblast-derived iPS cells were differentiated into limbal progenitor cells using limbal cell-specific (PI) medium and varying doses (1, 10, and 50 ng/mL) and durations (1, 3, and 10 days) of BMP4 treatment. Differentiated human iPS cells were analyzed by real-time polymerase chain reaction (RT-PCR), Western blotting, and immunocytochemical studies at 2 or 4 weeks after BMP4 treatment. Culturing human dermal fibroblast-derived iPS cells in limbal cell-specific medium and BMP4 gave rise to limbal progenitor and corneal epithelial-like cells. The optimal protocol of 10 ng/mL and three days of BMP4 treatment elicited significantly higher limbal progenitor marker (ABCG2, ∆Np63α) expression and less corneal epithelial cell marker (CK3, CK12) expression than the other combinations of BMP4 dose and duration. In conclusion, this study identified a successful reprogramming strategy to induce limbal progenitor cells from human iPS cells using limbal cell-specific medium and BMP4. Additionally, our experiments indicate that the optimal BMP4 dose and duration favor limbal progenitor cell differentiation over corneal epithelial cells and maintain the phenotype of limbal stem cells. These findings contribute to the development of therapies for limbal stem cell deficiency disorders.     

The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells

BMP10 is highly expressed in the developing heart and plays essential roles in cardiogenesis. BMP10 deletion in mice results in embryonic lethality because of impaired cardiac development. In adults, BMP10 expression is restricted to the right atrium, though ventricular hypertrophy is accompanied by increased BMP10 expression in a rat hypertension model. However, reports of BMP10 activity in the circulation are inconclusive. In particular, it is not known whether in vivo secreted BMP10 is active or whether additional factors are required to achieve its bioactivity. It has been shown that high-affinity binding of the BMP10 prodomain to the mature ligand inhibits BMP10 signaling activity in C2C12 cells, and it was proposed that prodomain-bound BMP10 (pBMP10) complex is latent. In this study, we demonstrated that the BMP10 prodomain did not inhibit BMP10 signaling activity in multiple endothelial cells, and that recombinant human pBMP10 complex, expressed in mammalian cells and purified under native conditions, was fully active. In addition, both BMP10 in human plasma and BMP10 secreted from the mouse right atrium were fully active. Finally, we confirmed that active BMP10 secreted from mouse right atrium was in the prodomain-bound form. Our data suggest that circulating BMP10 in adults is fully active and that the reported vascular quiescence function of BMP10 in vivo is due to the direct activity of pBMP10 and does not require an additional activation step. Moreover, being an active ligand, recombinant pBMP10 may have therapeutic potential as an endothelial-selective BMP ligand, in conditions characterized by loss of BMP9/10 signaling.     

人骨形态发生蛋白7在中国仓鼠卵巢细胞中的表达研究

目的:构建重组人骨形态发生蛋白-7(rhBMP7)表达质粒,并研究其在中国仓鼠卵巢细胞中的表达。方法:将hBMP7重组表达质粒电转到中国仓鼠卵巢细胞(CHO)中,并用DOT-BLOT和ELISA方法分析检测rhBMP7在重组CHO细胞中的表达。结果:hBMP7 cDNA整合到CHO细胞基因组中并被转录。点杂交和ELISA检测证实rhBMP7在CHO细胞中得到表达。结论:hBMP7成功在CHO表达系统中得到表达。     

全反式维甲酸抑制猪脂肪间充质干细胞的成脂分化

分离培养猪脂肪间充质干细胞（adipose mesenchymal stem cells, AMSCs）,流式细胞仪鉴定其表面标记.利用MTT比色检测不同浓度的全反式维甲酸（all trans retinoic acid, ATRA）对猪AMSCs增殖的影响;光学显微镜下观察猪AMSCs向脂肪细胞分化的形态学变化;油红O染色提取法分析不同浓度ATRA对猪AMSCs成脂分化的影响;RT PCR检测脂肪细胞分化标志基因LPL和aP2 mRNA的变化.MTT比色结果显示,生理浓度（1×10^－9～1×10^－8 mol/L）和药理浓度（1×10^－7～1×10^－5 mol/L）ATRA对猪AMSCs增殖均没有影响.油红O染色提取法结果表明,除1×10^－7　mol/L ATRA对猪AMSCs成脂分化没有影响外,生理浓度（1×10^－9～1×10^－8 mol/L）和其它药理浓度（1×10^－6～1×10^－5 mol/L）ATRA均显著抑制猪AMSCs成脂分化（P<0.05）.RT-PCR检测显示,ATRA显著抑制脂肪细胞分化标志基因LPL和aP2 mRNA表达（P<0.05）.     

Bone Morphogenetic Proteins Signal Via SMAD and Mitogen-activated Protein (MAP) Kinase Pathways at Distinct Times during Osteoclastogenesis

To investigate the role of bone morphogenetic protein (BMP) signaling in osteoclastogenesis in vivo, we eliminated BMPRII in osteoclasts by creating a BMPRII^fl/fl;lysM-Cre mouse strain. Conditional knock-out (cKO) mice are osteopetrotic when compared with WT controls due to a decrease in osteoclast activity. Bone marrow macrophages (BMMs) isolated from cKO mice are severely inhibited in their capacity to differentiate into mature osteoclasts in the presence of M-CSF and receptor activator of NF-κB (RANK) ligand. We also show that BMP noncanonical (MAPK) and canonical (SMAD) pathways are utilized at different stages of osteoclast differentiation. BMP2 induces p38 phosphorylation in pre-fusion osteoclasts and increases SMAD phosphorylation around osteoclast precursor fusion. Phosphorylation of MAPKs was decreased in differentiated BMMs from cKO animals. Treating BMMs with the SMAD inhibitor dorsomorphin confirms the requirement for the canonical pathway around the time of fusion. These results demonstrate the requirement for BMP signaling in osteoclasts for proper bone homeostasis and also explore the complex signaling mechanisms employed by BMP signaling during osteoclast differentiation.     

重组人骨形成蛋白-3羧基端肽在大肠杆菌中表达及其诱骨活性

以双顺反子表达载体,在大肠杆菌中经ＩＰＴＧ诱导表达了人骨形成蛋白－３羧基端肽段（ｈＢＭＰ－３Ｃ）,表达量占菌体总蛋白量的１８．５％．目的蛋白为２５ｋＤ、含ｈＢＭＰ－３Ｃ端２１５个氨基酸残基组成的肽段,包括ｈＢＭＰ－３成熟肽和一部分前肽．表达产物以包涵体的形式存在,用含ＴｒｉｔｏｎＸ－１００的洗涤液和５ｍｏｌ／Ｌ以下脲溶液连续洗涤,可获得较高纯度的重组人骨形成蛋白－３Ｃ端肽．经复性处理成可溶性蛋白,植入小鼠肌肉内,第１４ｄ组织切片显示有软骨细胞和软骨基质形成,第２１ｄ可见成骨细胞和骨基质形成．将ｒｈＢＭＰ－３Ｃ与脱矿去免疫原性异种骨粒复合后作小鼠肌肉植入试验,２１ｄ组织切片上可见硬质骨形成．结果表明：大肠杆菌表达的ｈＢＭＰ－３Ｃ经复性后具有诱骨活性,糖基化并非ＢＭＰ－３活性所必需．